Meridian Bioscience Inc. (VIVO): Price and Financial Metrics


Meridian Bioscience Inc. (VIVO)

Today's Latest Price: $17.59 USD

1.41 (-7.42%)

Updated Nov 23 6:55pm

Add VIVO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

VIVO Stock Summary

  • With a year-over-year growth in debt of 53.92%, Meridian Bioscience Inc's debt growth rate surpasses 82.67% of about US stocks.
  • Over the past twelve months, VIVO has reported earnings growth of 72.48%, putting it ahead of 85.22% of US stocks in our set.
  • The volatility of Meridian Bioscience Inc's share price is greater than that of 84.52% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Meridian Bioscience Inc, a group of peers worth examining would be CTS, ULBI, CRTO, SCL, and AMOT.
  • VIVO's SEC filings can be seen here. And to visit Meridian Bioscience Inc's official web site, go to www.meridianbioscience.com.

VIVO Stock Price Chart Interactive Chart >

Price chart for VIVO

VIVO Price/Volume Stats

Current price $17.59 52-week high $26.58
Prev. close $19.00 52-week low $5.51
Day low $17.42 Volume 744,800
Day high $19.20 Avg. volume 729,601
50-day MA $17.75 Dividend yield N/A
200-day MA $15.56 Market Cap 753.96M

Meridian Bioscience Inc. (VIVO) Company Bio


Meridian Biosciences is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. The company was founded in 1976 and is based in Cincinnati, Ohio.

VIVO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$17.59$6.78 -64%

Below please find a table outlining a discounted cash flow forecast for VIVO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Meridian Bioscience Inc ranked in the 25th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Meridian Bioscience Inc ended up being:

  • The company's compound free cash flow growth rate over the past 5.5 years comes in at -0.01%; that's greater than only 23.15% of US stocks we're applying DCF forecasting to.
  • The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than only 0% of stocks in its sector (Healthcare).


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-65%
1%-65%
2%-64%
3%-64%
4%-64%
5%-63%

Want more companies with a valuation profile/forecast similar to that of Meridian Bioscience Inc? See A, ABC, BIO, LGND, and SNN.


VIVO Latest News Stream


Event/Time News Detail
Loading, please wait...

VIVO Latest Social Stream


Loading social stream, please wait...

View Full VIVO Social Stream

Latest VIVO News From Around the Web

Below are the latest news stories about Meridian Bioscience Inc that investors may wish to consider to help them evaluate VIVO as an investment opportunity.

Meridian launches antibody pair for COVID-19 saliva tests

Meridian Bioscience ([[VIVO]] -1.1%) announces the availability of a SARS-CoV-2 antibody pair designed specifically for the development of COVID-19 antigen tests using saliva samples.It says the antibodies recognize a linear epitope of the SARS-CoV-2 trimeric protein with picogram/mL sensitivity while avoiding reactivity with other coronaviruses such as SARS-CoV, HCoV-229F, HCoV-HKUI,...

Seeking Alpha | September 14, 2020

Meridian Bio gains after boosted, consensus-beating guidance

Meridian Bioscience ([[VIVO]]) fiscal Q3 results:Revenues: $84.8M (+75.2%); Life Science: $63.2M (+313.1%); Diagnostics $21.6M (-34.7%).Net Income: $27.5M (+439.2%); EPS: $0.64 (+433.3%); non-GAAP Net Income: $24M (+242.9%); non-GAAP EPS: $0.56 (+250.0%).2020 Guidance: Revenues: $245M - 250M from $230M - 236M vs. average analyst estimates of $233.48M; Life Science revenue: $127M -...

Seeking Alpha | August 7, 2020

Meridian Bioscience (VIVO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 31, 2020

Benzinga's Top Upgrades, Downgrades For July 27, 2020

Upgrades * For First Community Corp (NASDAQ: FCCO), Raymond James upgraded the previous rating of Market Perform to the current rating Outperform. In the second quarter, First Community showed an EPS of $0.30, compared to $0.37 from the year-ago quarter. At the moment, the stock has a 52-week-high of $22.00 and a 52-week-low of $12.51. First Community closed at $13.66 at the end of the last trading period. * Raymond James upgraded American Airlines Group (NASDAQ:AAL) from Underperform to Market Perform. American Airlines shares closed at $11.39 on Friday. * Goldman Sachs upgraded Tapestry (NYSE:TPR) from Neutral to Buy. Tapestry shares closed at $13.47 on Friday. * Citigroup upgraded the previous rating for Schlumberger Ltd (NYSE: SLB) from Neutral to Buy. For the second quarter, Schlum...

Yahoo | July 27, 2020

Meridian Bioscience to Hold Third Quarter 2020 Financial Results Conference Call on August 7, 2020

CINCINNATI, July 16, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter 2020.

Yahoo | July 16, 2020

Read More 'VIVO' Stories Here

VIVO Price Returns

1-mo -4.04%
3-mo 11.61%
6-mo 24.05%
1-year 94.58%
3-year 22.41%
5-year 1.85%
YTD 80.04%
2019 -43.29%
2018 28.02%
2017 -18.02%
2016 -9.91%
2015 30.17%

Continue Researching VIVO

Want to see what other sources are saying about Meridian Bioscience Inc's financials and stock price? Try the links below:

Meridian Bioscience Inc (VIVO) Stock Price | Nasdaq
Meridian Bioscience Inc (VIVO) Stock Quote, History and News - Yahoo Finance
Meridian Bioscience Inc (VIVO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7393 seconds.